華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

The board (the "**Board**") of directors (the "**Directors**") of China Resources Pharmaceutical Group Limited (the "**Company**" or "**China Resources Pharmaceutical**") is pleased to announce the unaudited condensed consolidated interim results of the Company and its subsidiaries (the "**Group**") for the six months ended 30 June 2026 (the "**Reporting Period**"), together with the comparative figures for the previous year/period as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS

For the six months ended 30 June 2026 — unaudited
*(Expressed in Renminbi ("**RMB**"))*

		Six months ended 30 June	
		2026	2025
	Note	***RMB'000***	*RMB'000*
Revenue	*4*	**134,457,581**	131,866,817
Cost of sales		**(112,923,458)**	(110,357,203)
Gross profit		**21,534,123**	21,509,614
Other income	*5*	**850,264**	849,442
Other gains and losses	*6*	**(710,065)**	(1,086,255)
Selling and distribution expenses		**(10,145,719)**	(10,010,130)
Administrative expenses		**(3,344,477)**	(3,186,557)
Other expenses, net		**(1,164,836)**	(1,038,382)
Finance income		**200,462**	271,275
Finance costs		**(909,064)**	(1,006,278)
Finance costs, net	*7*	**(708,602)**	(735,003)

	Note	Six months ended 30 June	
		2026	2025
		RMB'000	*RMB'000*
Share of profits of associates and joint ventures		**134,088**	113,236
Profit before taxation	*8*	**6,444,776**	6,415,965
Income tax	*9*	**(1,421,271)**	(1,362,328)
Profit for the period		**5,023,505**	5,053,637
Attributable to:			
Equity shareholders of the Company		**2,186,632**	2,077,282
Non-controlling interests		**2,836,873**	2,976,355
		5,023,505	5,053,637
Earnings per share attributable to ordinary equity shareholders of the Company:	*10*		
Basic and diluted *(RMB)*		**0.35**	0.33

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 June 2026 — unaudited
(Expressed in RMB)

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Profit for the period	**5,023,505**	5,053,637
Other comprehensive income for the period		
Items that are or may be reclassified subsequently to profit or loss:		
Exchange differences on translation of operations outside Chinese Mainland	**(60,471)**	(16,654)
Share of other comprehensive income of associates	**(50)**	144
	(60,521)	(16,510)
Item that will not be reclassified to profit or loss:		
Share of other comprehensive income of associates	**(50,508)**	1,361
Other comprehensive income for the period, net of tax	**(111,029)**	(15,149)
Total comprehensive income for the period	**4,912,476**	5,038,488
Attributable to:		
Equity shareholders of the Company	**2,142,929**	2,065,943
Non-controlling interests	**2,769,547**	2,972,545
Total comprehensive income for the period	**4,912,476**	5,038,488

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2026 — unaudited
(Expressed in RMB)

	Note	**30 June 2026** ***RMB'000***	31 December 2025 *RMB'000*
Non-current assets			
Property, plant and equipment	*12*	**26,259,580**	26,189,147
Right-of-use assets		**6,187,704**	6,221,696
Investment properties		**1,789,029**	1,754,483
Intangible assets		**11,049,990**	11,202,572
Goodwill		**24,354,411**	24,342,134
Interests in associates		**6,373,882**	6,263,074
Interests in joint ventures		**62,746**	78,969
Other non-current financial assets	*13*	**839,383**	844,185
Deferred tax assets		**2,538,831**	2,374,562
Other non-current assets		**5,030,846**	4,833,403
Total non-current assets		**84,486,402**	84,104,225
Current assets			
Inventories		**45,073,185**	43,270,875
Trade and other receivables	*14*	**112,013,502**	104,567,691
Other current financial assets	*15*	**24,404,620**	25,251,884
Amounts due from related parties		**965,900**	879,711
Tax recoverable		**122,489**	219,736
Pledged and term deposits		**11,591,787**	11,635,245
Cash and cash equivalents		**15,622,384**	15,843,809
		209,793,867	201,668,951
Assets classified as held for sale		**35,326**	37,996
Total current assets		**209,829,193**	201,706,947

	Note	30 June 2026 RMB'000	31 December 2025 RMB'000
Current liabilities			
Trade and other payables	*16*	**87,652,546**	85,853,303
Contract liabilities		**3,196,004**	4,141,731
Lease liabilities		**386,155**	492,936
Amounts due to related parties		**838,349**	909,112
Borrowings		**52,930,737**	47,670,390
Bonds payable		**1,254,418**	2,165,961
Tax payable		**657,715**	917,900
Defined benefit obligations		**43,975**	57,824
Total current liabilities		**146,959,899**	142,209,157
Net current assets		**62,869,294**	59,497,790
Total assets less current liabilities		**147,355,696**	143,602,015
Non-current liabilities			
Borrowings		**6,461,296**	11,149,853
Bonds payable		**16,724,264**	10,196,868
Lease liabilities		**731,577**	730,025
Deferred tax liabilities		**2,174,525**	2,131,060
Defined benefit obligations		**733,554**	744,514
Other non-current liabilities		**1,206,741**	1,193,762
Total non-current liabilities		**28,031,957**	26,146,082
NET ASSETS		**119,323,739**	117,455,933
CAPITAL AND RESERVES			
Share capital		**24,630,493**	24,630,493
Reserves		**28,165,957**	26,777,982
Total equity attributable to equity shareholders of the Company		**52,796,450**	51,408,475
Non-controlling interests		**66,527,289**	66,047,458
TOTAL EQUITY		**119,323,739**	117,455,933

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

(Expressed in RMB unless otherwise indicated)

1. CORPORATE INFORMATION

The Company is a public limited company incorporated in Hong Kong and its shares are listed on The Stock Exchange of Hong Kong Limited with effect from 28 October 2016. The address of the registered office of the Company is 41/F, China Resources Building, 26 Harbour Road, Wanchai, Hong Kong. The Group is principally engaged in the manufacture, distribution and retail of pharmaceutical and healthcare products.

2. BASIS OF PREPARATION AND CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

2.1. Basis of preparation

The interim financial report for the six months ended 30 June 2026 has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with Hong Kong Accounting Standard ("**HKAS**") 34 *Interim financial reporting*, issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**"). It was approved and authorised for issue by the board of directors on 24 August 2026.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2025 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2026 annual financial statements. Details of any changes in accounting policies are set out in Note 2.2.

The preparation of the interim financial report in conformity with HKAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of the Group since the 2025 annual financial statements. The condensed consolidated interim financial statements and the accompanying notes do not include all of the information required for a full set of financial statements prepared in accordance with HKFRS Accounting Standards.

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the HKICPA.

The financial information relating to the financial year ended 31 December 2025 that is included in the interim financial report as comparative information does not constitute the Company's statutory annual consolidated financial statements for that financial year, but is derived from those financial statements. Further information relating to these statutory financial statements disclosed in accordance with section 436 of the Hong Kong Companies Ordinance (Cap. 622) is as follows:

The Company has delivered the financial statements for the year ended 31 December 2025 to the Registrar of Companies as required by section 662(3) of, and Part 3 of Schedule 6 to, the Companies Ordinance.

The Company's auditor has reported on those financial statements. The auditor's report was unqualified; did not include a reference to any matters to which the auditor drew attention by way of emphasis without qualifying its report; and did not contain a statement under section 406(2), 407(2) or (3) of the Companies Ordinance.

2.2. Changes in accounting policies

The HKICPA has issued a number of amendments to HKFRS Accounting Standards that are first effective for the current accounting period. Of these, only the amendments to HKFRS 9, *Financial instruments* and HKFRS 7, *Financial instruments: Disclosures — Amendments to the classification and measurement of financial instruments*, are relevant to the Group's financial statements. The amendments do not have a material impact on this interim financial report.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period. The management is assessing the impact of such standards and will adopt the relevant standards in the subsequent periods as required.

3. SEGMENT INFORMATION

Management has determined the operating segments based on the reports reviewed by the board of directors that are used to make strategic decisions. The board of directors of the Company, being the chief operating decision maker ("**CODM**"), considers resource allocation and assesses segment performance from a different business type perspective.

Specifically, the Group has four reportable operating segments as follows:

(a) Pharmaceutical manufacturing business (Manufacturing segment) — research and development, manufacture and sale of a broad range of pharmaceutical and healthcare products;

(b) Pharmaceutical distribution business (Distribution segment) — distribution, warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical devices manufacturers and dispensers, such as hospitals, distributors and retail pharmacies;

(c) Pharmaceutical retail business (Retail segment) — operation of retailing of pharmacy stores;

(d) Other business operations (Others) — property holding and others.

No operating segments have been aggregated to derive the reportable segments of the Group.

Inter-segment sales are conducted at prices and terms mutually agreed amongst those operating segments, with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

The board of directors assesses the performance of the operating segments on the following bases:

Segment results represent the profit earned by each segment without allocation of other income, other gains and losses, administrative expenses, other expenses, finance income, non-leased-related finance costs and share of profits of associates and joint ventures. This is the measure reported to the CODM for the purposes of resource allocation and performance assessment.

The following tables present revenue and results for the Group's operating segments for the six months ended 30 June 2026 and 2025:

Six months ended 30 June 2026	Manufacturing segment *RMB'000*	Distribution segment *RMB'000*	Retail segment *RMB'000*	Others *RMB'000*	Total *RMB'000*
Segment revenue					
External sales	**21,716,989**	**106,348,583**	**6,337,213**	**54,796**	**134,457,581**
Inter-segment sales	**2,727,662**	**4,646,231**	**–**	**–**	**7,373,893**
	24,444,651	**110,994,814**	**6,337,213**	**54,796**	**141,831,474**
Elimination:					
Elimination of inter-segment sales					**(7,373,893)**
Revenue					**134,457,581**
Segment results	**7,472,880**	**3,765,240**	**102,548**	**20,551**	**11,361,219**
Other income *(Note 5)*					**850,264**
Other gains and losses *(Note 6)*					**(710,065)**
Administrative expenses					**(3,344,477)**
Other expenses, net					**(1,164,836)**
Finance income *(Note 7)*					**200,462**
Finance costs (other than interest on lease liabilities)					**(881,879)**
Share of profits of associates and joint ventures					**134,088**
Profit before taxation					**6,444,776**

Six months ended 30 June 2025	Manufacturing segment *RMB'000*	Distribution segment *RMB'000*	Retail segment *RMB'000*	Others *RMB'000*	Total *RMB'000*
Segment revenue					
External sales	21,828,091	104,453,805	5,514,645	70,276	131,866,817
Inter-segment sales	2,980,189	3,875,922	–	–	6,856,111
	24,808,280	108,329,727	5,514,645	70,276	138,722,928
Elimination:					
Elimination of inter-segment sales					(6,856,111)
Revenue					131,866,817
Segment results	7,442,942	3,897,856	79,316	46,766	11,466,880
Other income *(Note 5)*					849,442
Other gains and losses *(Note 6)*					(1,086,255)
Administrative expenses					(3,186,557)
Other expenses, net					(1,038,382)
Finance income *(Note 7)*					271,275
Finance costs (other than interest on lease liabilities)					(973,674)
Share of profits of associates and joint ventures					113,236
Profit before taxation					6,415,965

4. REVENUE

An analysis of the Group's revenue is as follows:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Revenue from contracts with customers within the scope of HKFRS 15 recognised at point in time		
Sale of pharmaceutical products	**134,399,446**	131,793,391
Revenue from other sources		
Gross rental income from investment property under operating leases	**58,135**	73,426
	134,457,581	131,866,817
Revenue disaggregated by geographical markets		
Chinese Mainland	**133,854,228**	131,344,541
Hong Kong and others	**603,353**	522,276
	134,457,581	131,866,817

5. OTHER INCOME

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Service fee income	**425,529**	305,333
Government grants	**203,112**	324,586
Others	**221,623**	219,523
	850,264	849,442

6. OTHER GAINS AND LOSSES

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Impairment recognised on intangible assets	**(53,277)**	(32,803)
Impairment recognised on interests in associates	**–**	(392,463)
Impairment recognised on trade and other receivables, net	**(643,461)**	(608,800)
Gain on disposal of items of property, plant and equipment and right-of-use assets, net	**5,728**	4,920
Loss on derecognition of trade and bills receivables measured at fair value through other comprehensive income	**(95,093)**	(88,870)
Fair value changes of financial assets at fair value through profit or loss	**16,461**	61,247
Gain/(loss) on disposal of subsidiaries and associates	**22,567**	(955)
Others	**37,010**	(28,531)
	(710,065)	(1,086,255)

7. FINANCE COSTS, NET

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Finance costs:		
Interest on borrowings	**732,040**	886,787
Interest on bonds payable	**147,433**	85,938
Interest on borrowings from an intermediate holding company	**1,228**	–
Interest on lease liabilities	**27,185**	32,604
Interest on defined benefit obligations	**2,315**	2,161
Less: Interest capitalised in property, plant and equipment *(Note)*	**(1,137)**	(1,212)
Total finance costs	**909,064**	1,006,278
Finance income — Interest income	**(200,462)**	(271,275)
Net finance costs	**708,602**	735,003

Note: The capitalisation rate is 2.88% for the period (six months ended 30 June 2025: 3.15%–3.50%).

8. PROFIT BEFORE TAXATION

The Group's profit before taxation is arrived at after charging:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Cost of inventories*	**112,162,435**	109,630,879
Research and development expenditure (included in other expenses)	**1,112,513**	970,848
Depreciation of property, plant and equipment	**1,333,794**	1,171,848
Depreciation of right-of-use assets	**418,643**	396,758
Amortisation of intangible assets	**370,480**	318,947
Allowance for slow-moving and obsolete inventories	**71,306**	15,736
Lease expenses not included in the measurement of lease liabilities	**66,568**	61,494
Foreign exchange loss, net	**2,847**	5,792

* Cost of inventories relating to depreciation is also included in the respective total amounts disclosed separately above.

9. INCOME TAX

The Group calculates income tax expense for the period using the tax rate that would be applicable to the expected total annual earnings.

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Enterprise Income Tax		
Provision for the period	**1,535,516**	1,616,963
Origination and reversal of temporary differences	**(114,245)**	(254,635)
	1,421,271	1,362,328

The provision for Hong Kong Profits Tax for 2026 is calculated at 16.5% (six months ended 30 June 2025: 16.5%) of the estimated assessable profits for the period.

Under the Law of PRC on Enterprise Income Tax (the "**EIT Law**") and Implementation Regulation of the EIT Law, the tax rate of PRC subsidiaries is 25%. In accordance with the relevant tax rules in the PRC, certain subsidiaries of the Group enjoy various income tax reductions.

10. EARNINGS PER SHARE

The calculation of the basic earnings per share is based on:

	Six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Earnings		
Profit attributable to equity shareholders of the Company used in the basic earnings per share calculation	**2,186,632**	2,077,282
Less: Forfeitable dividends declared to owners of the restricted shares of subsidiaries during the period	**(411)**	(3,954)
Profit attributable to ordinary equity shareholders of the Company used in the basic earnings per share calculation	**2,186,221**	2,073,328

	Six months ended 30 June	
	2026	2025
Number of shares		
Weighted average number of ordinary shares in issue during the period used in the basic earnings per share calculation	**6,282,510,461**	6,282,510,461

The restricted share incentive schemes of China Resources Jiangzhong Pharmaceutical Co., Ltd., China Resources Double Crane Pharmaceutical Co., Ltd. and Dong-E-E-Jiao Company Limited have an immaterial impact, the basic and diluted earnings per share are the same.

11. DIVIDENDS

(a) Dividends declared after the end of the reporting period

On 24 August 2026, the directors of the Company resolved to declare an interim dividend of RMB0.087 per ordinary share, in an aggregate amount of RMB547 million for the six months ended 30 June 2026 (six months ended 30 June 2025: RMB452 million). Dividends declared after the end of the reporting period are not recognised as a liability at the end of the reporting period.

(b) Dividends declared during the period

	2026	2025
	RMB'000	*RMB'000*
Dividend for ordinary shareholders of the Company recognised as distribution during the period: Final 2025 — RMB0.122 per ordinary share (2025: Final 2024 — RMB0.052 per ordinary share)	**765,873**	326,691

A final dividend in respect of the year ended 31 December 2025 of RMB0.122 per ordinary share, in an aggregate amount of RMB766 million, was approved at the annual general meeting of the Company on 12 June 2026 and remained unpaid to the shareholders of the Company as at the end of the reporting period.

12. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2026, the Group acquired property, plant and equipment approximately amounting to RMB1,298,275,000 (six months ended 30 June 2025: RMB1,225,102,000), excluding the property, plant and equipment acquired through business combinations.

Assets with a net book value of approximately RMB40,613,000 were disposed of by the Group during the six months ended 30 June 2026 (six months ended 30 June 2025: RMB19,926,000), resulting in a net gain on disposal of approximately RMB5,728,000 (six months ended 30 June 2025: a net gain on disposal of approximately RMB606,000).

13. OTHER NON-CURRENT FINANCIAL ASSETS

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
Equity investments, at fair value through other comprehensive income *(Note a)*	**10,943**	10,943
Equity investments, at fair value through profit or loss *(Note b)*	**828,440**	833,242
	839,383	844,185

Note a: The Group's equity investments at fair value through other comprehensive income represented investments in unlisted entities established in the PRC. These entities are principally engaged in pharmaceutical related operations.

Note b: The Group's equity investments at fair value through profit or loss represented investments in entities. These entities are principally engaged in research and development, distribution and related operations of pharmaceutical products.

14. TRADE AND OTHER RECEIVABLES

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
Bills receivable	**369,454**	586,483
Contract assets	**41,873**	55,494
Trade receivables	**102,363,502**	95,143,029
Impairment allowance	**(3,961,511)**	(3,316,908)
	98,401,991	91,826,121
Prepayments	**3,951,689**	4,006,099
Other receivables	**9,665,340**	8,509,220
Impairment allowance	**(416,845)**	(415,726)
	9,248,495	8,093,494
	112,013,502	104,567,691

The Group generally allows credit periods, ranging from 30 to 365 days, to its trade customers. The bills receivable generally has maturity periods ranging from 30 to 180 days.

An ageing analysis of the Group's trade receivables as at the end of the reporting period, based on the invoice date and net of impairment allowance, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
0 to 30 days	**20,604,843**	23,172,013
31 to 60 days	**13,082,191**	13,429,908
61 to 90 days	**11,099,043**	7,995,247
91 to 180 days	**21,086,617**	19,328,359
181 to 365 days	**23,260,986**	20,811,679
Over 1 year	**9,268,311**	7,088,915
	98,401,991	91,826,121

An ageing analysis of the Group's bills receivable as at the end of reporting period, based on the issue date, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
0 to 30 days	**244,873**	371,032
31 to 60 days	**21,867**	46,505
61 to 90 days	**45,723**	40,561
91 to 180 days	**56,991**	128,385
	369,454	586,483

15. OTHER CURRENT FINANCIAL ASSETS

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
Trade and bills receivables, at fair value *(Note a)*	**13,525,522**	13,182,843
Financial products, at fair value *(Note b)*	**10,844,784**	11,965,901
Equity investments, at fair value through profit or loss	**34,314**	103,140
	24,404,620	25,251,884

Note a: The Group has classified trade and bills receivables that are held within a business model both to collect cash flows and to sell financial assets at fair value through other comprehensive income.

Note b: Financial products at fair value included structured deposits entered into by the Group with banks and financial institutions.

16. TRADE AND OTHER PAYABLES

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
Trade payables	**45,529,468**	42,830,197
Bills payable	**20,297,849**	21,745,649
Accrued salaries	**3,432,791**	4,155,106
Other tax payables	**973,946**	1,097,579
Other payables	**15,859,236**	14,502,768
Refund liabilities	**1,321,619**	1,337,454
Payable for acquisitions of subsidiaries	**237,637**	184,550
	87,652,546	85,853,303

The credit period for purchases of goods ranges from 30 to 90 days. The bills payable have maturity periods ranging from 30 to 180 days. As at 30 June 2026, the Group's bills payable of RMB15,860,163,000 (31 December 2025: RMB18,971,089,000) were secured by the Group's bills receivable with an aggregate carrying amount of RMB60,452,000 (31 December 2025: RMB164,102,000) and pledged bank deposits of RMB5,723,344,000 (31 December 2025: RMB6,373,141,000).

An ageing analysis of the Group's trade payables, based on the invoice date, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
0 to 30 days	**22,452,949**	22,191,799
31 to 60 days	**7,952,844**	7,771,663
61 to 90 days	**4,127,469**	3,149,419
Over 90 days	**10,996,206**	9,717,316
	45,529,468	42,830,197

An ageing analysis of the Group's bills payable, based on the issue date, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
0 to 30 days	**5,199,961**	7,138,675
31 to 60 days	**3,250,457**	3,372,965
61 to 90 days	**3,281,835**	3,209,723
Over 90 days	**8,565,596**	8,024,286
	20,297,849	21,745,649

INDUSTRY OVERVIEW

Since 2026, despite the complex and volatile external environment, China's economy has maintained an overall stable development trend with progress toward high-quality and innovation-driven growth. New drivers of growth have accelerated, and people's livelihood has been firmly safeguarded. According to data from the National Bureau of Statistics, China's GDP grew by 4.7% year-on-year in the first half of 2026, maintaining a leading position among the major global economies and continuing to demonstrate strong resilience and vitality.

China's pharmaceutical industry remains in a structural adjustment period characterized by existing business optimization and incremental expansion of innovative drugs and medical devices, with industry growth trending toward stabilization and bottoming out. According to data from the National Bureau of Statistics, during the first half of 2026, pharmaceutical manufacturers above designated size in China achieved operating revenue of RMB1,171.78 billion, remaining flat year-on-year; and achieved total profit of RMB177.32 billion, representing a year-on-year increase of 4.2%. In 2026, the biomedical industry was, for the first time, included as an emerging pillar industry under national support. With the further implementation of various policies under the "Healthy China" initiative, the continued release of demand driven by population aging and growing health awareness, and the rapid enhancement of enterprises' innovation and internationalization capabilities, the pharmaceutical industry is expected to maintain steady development.

From the perspective of segmented fields, traditional Chinese medicine ("**TCM**") is moving toward a stage of high-quality development. The Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry (2026–2030) proposes to promote steady improvement in the scale and efficiency of the TCM industry and to cultivate a group of TCM industry flagship enterprises with prominent leading and driving capabilities. Innovative drugs and high-end medical devices have demonstrated strong growth momentum driven by technological upgrading, domestic substitution, and internationalization. Cutting-edge therapeutic modalities such as cell and gene therapy, antibody-drug conjugates (ADCs), and small nucleic acid drugs are undergoing rapid iterative development; artificial intelligence is empowering all aspects of the pharmaceutical industry in an all-round manner, facilitating efficiency enhancement and business model transformation.

China has further deepened healthcare reforms, promoting coordinated development and governance among healthcare, medical insurance, and pharmaceuticals, and driving industry transformation, upgrading, and high-quality development. The new version of the Implementing Regulations of the Drug Administration Law encourages the research and development ("**R&D**") of new drugs, promotes the inheritance and innovation of TCM and the R&D innovation of generic drugs, and establishes the primary responsibility of drug marketing authorization holders for the entire life cycle of drugs. The Several Opinions on Improving the Drug Pricing Mechanism supports high-level innovative drugs in obtaining price returns commensurate with high investment and high risks. The simultaneous adjustment of the basic medical insurance catalog and the commercial insurance innovative drug catalog has opened up new space for the development of innovative drugs. The normalization and institutionalization of centralized procurement have brought downward pricing pressure to the industry, but have also emphasized the prevention of intensifying intra-industry competition. The full implementation of DRG/DIP (Diagnosis-Related Groups/Diagnosis-Intervention Packet) payment methods has made value-based healthcare an industry trend, although the growth of hospital pharmaceutical markets has faced pressure in the short term. The introduction of policies such as the Measures for the Administration of Pharmaceutical Representatives has significantly regulated pharmaceutical promotion practices and further purified the industry ecosystem.

Overall, against the backdrop of reshaping industry development logic and accelerating structural adjustments, the operational disparities among enterprises have further widened. Companies with strong comprehensive capabilities, rapid innovation-driven transformation, and high brand barriers have demonstrated stronger resilience against risks and the ability to navigate through market cycles.

GROUP RESULTS AND HIGHLIGHTS

During the Reporting Period, the Group actively supported national strategies, fostered new quality productive forces in the pharmaceutical sector, and prioritized the strategic layout of emerging industries. It implemented multiple measures to drive R&D innovation, strengthened external mergers and acquisitions, synergistic integration and product introduction, enhanced the digital and intelligent transformation and green and low-carbon development, continuously optimised its business structure and operational quality, and promoted high-quality and sustainable development.

The Group maintains a leading position in terms of comprehensive influence within China's pharmaceutical industry. As an integrated pharmaceutical leader with strengths in manufacturing and distribution, the Group ranks second among the Top 100 pharmaceutical manufacturers for its pharmaceutical manufacturing business, and third in the industry for its pharmaceutical distribution business scale.

1. Financial Performance

During the Reporting Period, the Group recorded total revenue of RMB134,457.6 million, representing an increase of 2.0% compared to RMB131,866.8 million in the same period last year. In the first half of 2026, the revenue of three major business segments, namely pharmaceutical manufacturing, pharmaceutical distribution, and pharmaceutical retail and others, accounted for 16.2%, 79.1% and 4.7% of total revenue, respectively.

During the Reporting Period, the Group recorded a gross profit of RMB21,534.1 million, representing an increase of 0.1% from RMB21,509.6 million for the same period last year. The overall gross profit margin was 16.0%, representing a slight decrease of 0.3 percentage point compared to the first half of 2025.

During the Reporting Period, the Group recorded a net profit of RMB5,023.5 million, representing a slight decrease of 0.6% from RMB5,053.6 million for the first half of 2025. The Group generated a profit attributable to owners of the Company of RMB2,186.6 million, representing a steady increase of 5.3% compared with that of RMB2,077.3 million for the first half of 2025. Basic earnings per share were RMB0.35 during the Reporting Period (RMB0.33 in the first half of 2025). The Board has declared an interim dividend of RMB0.087 per share for the six months ended 30 June 2026 (2025 interim dividend was RMB0.072), representing a year-on-year increase of approximately 21%.

2. Pharmaceutical Manufacturing Business

(1) Financial performance

During the Reporting Period, the Group's pharmaceutical manufacturing business generated segment revenue of RMB24,444.7 million, representing a year-on-year slight decrease of 1.5%.The gross profit margin of the pharmaceutical business was 60.3%, representing an increase of 1.0 percentage point compared with the same period last year.

(2) Operation overview

The Group owns a comprehensive portfolio of pharmaceutical products covering a wide range of therapeutic areas, including chemical drugs, biological drugs, TCM, and nutraceuticals. These fully cover all major therapeutic and disease areas that offer favorable business growth potential, such as cardiovascular and cerebrovascular diseases, alimentary tract, endocrine system, respiratory system, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, oncology, medicine for cough and cold, anti-infection drugs and psychoneurosis. As at the end of the Reporting Period, the Group had 90 production bases with a total of 983 products, of which 518 were included in the National Reimbursement Drug List and 238 were included in the National Essential Drug List. In 2026, more than 80 product specifications

of the Group were newly included in the revised National Essential Drugs Catalogue, covering a wide range of therapeutic areas, including cardiovascular and cerebrovascular diseases, neuropsychiatry, respiratory system, digestive system, anti-infectives, oncology and gynaecology. All of the Group's pharmaceutical manufacturing subsidiaries have established professional sales and marketing teams that cover over 100,000 medical institutions.

Sales revenue from pharmaceutical manufacturing business by product categories *(RMB' million)*		**In the first half of 2026**	**In the first half of 2025**	**Period-over-period growth**
TCM		**12,803.6**	**13,062.0**	**–2.0%**
including:	OTC (over-the-counter) drugs	8,219.2	8,656.4	–5.1%
	Prescription drugs	4,584.4	4,405.6	4.1%
Chemical drugs		**8,877.3**	**8,928.3**	**–0.6%**
including:	OTC drugs	2,497.7	2,490.4	0.3%
	Prescription drugs	5,699.3	5,775.6	–1.3%
	API	680.3	662.3	2.7%
Biological drugs		**943.2**	**1,269.6**	**–25.7%**
Nutraceuticals and others		**1,820.6**	**1,548.4**	**17.6%**
Total		**24,444.7**	**24,808.3**	**–1.5%**

In terms of product categories, the Group's revenue from the TCM business of pharmaceutical manufacturing segment was RMB12,803.6 million during the Reporting Period, representing a year-on-year decrease of 2.0%, of which revenue from the TCM OTC drug business declined by 5.1% year-on-year, mainly due to a decrease in revenue from cold and flu-related products resulting from a decline in influenza incidence; while revenue from the TCM prescription drug business increased by 4.1% year-on-year, primarily due to the acquisition of Tasly Pharmaceutical Group Co., Ltd. ("**Tasly Pharmaceutical**"). The chemical drug business recorded revenue of RMB8,877.3 million, representing a slight year-on-year decrease of 0.6%, of which revenue from the chemical OTC drug business increased by 0.3% year-on-year; revenue from the chemical prescription drug business decreased by 1.3% year-on-year, primarily due to reduced revenue from infusion and anti-infective products. Supported by synthetic biology technologies, revenue from active pharmaceutical ingredients (API) business increased by 2.7% year-on-year. During the Reporting Period, the biological drugs business achieved revenue of RMB943.2 million, representing a year-on-year decrease of 25.7%, mainly attributable to reduced revenue from blood products business. Revenue from nutraceuticals and other business amounted to RMB1,820.6 million, representing a year-on-year increase of 17.6%, primarily due to increased revenue from healthcare products such as peach blossom cake, donkey-hide gelatin powder and probiotics.

a. Strengthening external expansion and synergistic integration, and enhancing industrial chain diversification

Promoting external mergers and acquisitions. The Group continues to accelerate its external expansion, expand business models, and forge into high-potential sectors. In May 2026, Dong-E-E-Jiao Company Limited ("**Dong-E-E-Jiao**") finalized the acquisition of Dong-E-E-Jiao (Jilin) Pharmaceutical Co., Ltd. (東阿阿膠(吉林)藥業有限公司) ("**Dong-E-E-Jiao Jilin**", formerly known as Shuzhong Pharmaceutical (Jilin) Co., Ltd. (蜀中藥業(吉林)有限公司)). Dong-E-E-Jiao Jilin holds a leading number of deer-related drug approvals in China, with a rich product portfolio and sufficient production capacity. This acquisition will further support the development of its men's health brand "Royal Hunting Ground 1619" and enrich its product matrix.

Strengthening asset restructuring and resource integration. In June 2026, China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) ("**CR Double-Crane**") completed its acquisition of 100% equity interest in Nanjing Xinbai Pharmaceutical Co., Ltd. (南京新百藥業有限公司) ("**Nanjing Xinbai**"), a subsidiary of China Resources Boya Bio-pharmaceutical Group Company Limited (華潤博雅生物製藥集團股份有限公司) ("**CR Boya Bio-pharmaceutical**"). This asset restructuring enhances the synergy of internal resources, demonstrates the Group's coordination and integration capabilities, and enables CR Boya Bio-pharmaceutical to further focus on blood products business. It also facilitates CR Double-Crane to strengthen its biochemical injection product pipeline and establish a local R&D and innovation platform leveraging the pharmaceutical industry resources of Nanjing Xinbai.

Continuously promoting post-investment integration. Leveraging its advanced management concepts and operational capabilities, the Group has improved the operational quality and management standards of its acquired entities. China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司) ("**CR Sanjiu**") successfully completed the first-year integration with Tasly Pharmaceutical, promoting efficient synergy across strategy, R&D, marketing and management. In R&D, leveraging its research strengths in the modernisation of TCM, Tasly Pharmaceutical has established a R&D strategy of "dual-driven development of innovative TCM and advanced therapeutic drugs". In marketing, both parties jointly developed products such as 999 Andrographolide Dripping Pills (999穿心蓮內酯滴丸). Tasly Pharmaceutical expanded its terminal coverage and e-commerce collaboration via CR Sanjiu's sales channels and retail chain platforms. In management, Tasly Pharmaceutical has fully adopted China Resources Group's management system, resulting in significantly improved operational efficiency, with sustained mutual empowerment effects.

CR Boya Bio-pharmaceutical has systematically improved the operational quality, efficiency and core competitiveness of CR Boya Bio-pharmaceutical (Anhui) Co., Ltd. ("**Boya (Anhui)**", formerly known as Green Cross HK (China) Biological Products Co., Ltd. (綠十字(中國)生物製品有限公司)). Through strengthened plasma station management, Boya (Anhui) recorded a significant year-on-year increase of 16% in plasma collection volume during the Reporting Period. In terms of R&D and innovation, Boya (Anhui) obtained production approval for its manufacturing process modification project for Human Immunoglobulin (pH4) ahead of schedule, completed the process modification for the intravenous immunoglobulin product, and achieved significant improvements in product quality and viral safety, as well as a 50% increase in product yield.

Dong-E-E-Jiao has focused on the deep integration of its "Zhuangben" cistanche deserticola project, continuously deepening the integration of local resources in Alashan with the Dong-E-E-Jiao brand, showcasing its products at the China-Eurasia Expo, and accelerating the transformation of resource advantages into industrial value. In the first half of the year, the sales revenue of the "Zhuangben" series increased by over 220% year-on-year, and Qiwei Cistanche Wine (七味蓯蓉酒) was honored with the Gold Award at the 2026 "Zhongshi Cup" Fermented Food Innovation Competition.

Industrial fund investment synergy and management incubation achieved significant results. CR Pharmaceutical Industry Fund Phase I has fully entered its exit stage, having effectively fulfilled its core function of incubation and exploration. During the investment period of the fund, the Group facilitated CR Sanjiu's investment in Respirent Pharmaceutical Co., Ltd. ("**Respirent Pharmaceutical**") together with the fund, and obtained the exclusive distribution and promotion rights in Chinese Mainland for Respirent Pharmaceutical's core product, the Fluticasone Propionate and Salmeterol Xinafoate Inhalation Powder. This product received U.S. FDA approval for marketing in January 2026, becoming the first inhalation powder product independently developed by a Chinese pharmaceutical company to receive FDA approval, demonstrating the Group's "Fund + Industry" investment synergy and management incubation capabilities.

During the Reporting Period, the Phase II of the China Resources Pharmaceutical Industry Investment Fund has entered its investment period, with a focus on investments in chemical innovative drugs, biologics, high-end medical devices, and TCM tonic products, among others. In June 2026, it completed an investment in Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd. in the vaccine sector, laying the

foundation for the Group to build a vaccine industry platform and complete its biopharmaceutical industry chain layout. At the same time, CR Double-Crane Synthetic Biology Industry Fund actively advanced investments in synthetic biology, innovative drugs, biotech and other fields, targeting high-tech achievement commercialisation projects and high-growth enterprises, thereby comprehensively supporting the Group's strategic layout and synergistic development in strategic emerging businesses such as synthetic biology.

Strengthened construction of the industry chain platform. In upstream, the Group promoted the guarantee of key raw materials and high-quality development. CR Sanjiu, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. ("**CR Jiangzhong**") and KPC Pharmaceuticals, Inc ("**KPC**") deepened standardised cultivation and continuously advanced the standardised construction of Good Agricultural Practice for Chinese Crude Drugs (GAP) bases. CR Sanjiu established two national-level seed and seedling bases in Ya'an, Sichuan and Yunfu, Guangdong. Dong-E-E-Jiao established a direct procurement supply chain for donkey hide at source in overseas markets, achieving a breakthrough in its overseas direct procurement business for donkey hide from zero to one and further strengthening the supply of key raw materials. In midstream, the Group adhered to high technology and high standards, implemented whole-process quality control, and accelerated intelligent manufacturing and integrated R&D-production construction. KPC advanced the construction of the Mile Notoginseng High-Quality Development Base to create an intelligent, garden-style factory. In downstream, the Group integrated consumer data and clinical evidence-based medical research to optimise the industry chain in a feedback loop. CR Sanjiu, together with time-honoured brands, launched the "TCM Culture Co-Chain Initiative" and expanded sales of non-pharmaceutical health products through health stations; the second phase of CR Jiangzhong's smart decoction centre for Chinese herbal medicine pieces put into operation in May 2026, further enhancing its decoction service capabilities and effectively facilitating the development of its Chinese herbal medicine pieces business. In parallel, the Group firmly advanced its strategy of integrating chemical APIs and preparations. Leveraging two bases — Shenzhou Biology & Technology Co., Ltd. ("**Shenzhou Biology & Technology**") and Tiandong Pharmaceutical Co., Ltd., CR Double-Crane focused on synthetic biology and biochemical extraction, extending APIs toward high-value-added preparations, building a cost-advantage structure to drive profitability improvement.

b. Strengthening R&D innovation to forge new quality productive forces

The Group has always regarded R&D innovation as the core engine driving high-quality development, implementing national policies and responding to clinical needs. It pursues both independent R&D and external collaboration, focusing on major therapeutic areas such as cardiovascular, respiratory, anti-tumour, digestive metabolism, central nervous system, immunology, and ophthalmology, while continuously strengthening core R&D capabilities to build differentiated competitive advantages.

Continued increase in investment in technological innovation resources. During the Reporting Period, the Group's R&D expenditure amounted to RMB1.36 billion, representing a year-on-year increase of 8.7%, demonstrating its firm commitment and strategic focus on technological innovation. As at the end of the Reporting Period, the number of the Group's R&D team amounted to 3,699 personnel, with master's and doctoral degree holders accounting for over 44%.

Developing high-level independent innovation capabilities. The Group is dedicated to establishing a comprehensive R&D platform encompassing TCM, chemical drugs and biological drugs. It possesses two national key laboratories, four national engineering technology research centers, one national industrial innovation center, and one national-level International Science and Technology Cooperation Base of the Ministry of Science and Technology. The Group has also established a postdoctoral research workstation and has proactively deployed and built a synthetic biology technology platform with industrial scale capabilities, which has established a three-tier translation system covering R&D, pilot-scale testing and industrialisation, as well as 7 major technology platforms. During the Reporting Period, leveraging its national key laboratories and national and provincial-level technology platforms, the Group conducted R&D in areas such as classic prescriptions of TCM, modern TCM, AI-assisted drug design, target discovery, antibody and peptide drugs, and synthetic biology. The Group led or participated in four national-level research projects.

Deepening external collaboration and innovation deployment. The Group has continued to explore new models of external joint innovation and industry-academia-research collaboration to accelerate the commercialisation of R&D achievements and foster new quality productive forces. During the Reporting Period, focusing on critical challenges in the field of neurological diseases and research in cell and gene therapy, the Group entered into a joint establishment of the "Brain Science and Neurological Diseases Joint Research Center" with Shenzhen Bay Laboratory, and jointly established a cell and gene therapy

joint laboratory with Shenzhen Third People's Hospital, with the first collaborative project officially initiated. Around key strategic areas aligned with the "Healthy China 2030" initiative, such as Alzheimer's disease and metabolic disorders, the Group's multiple cutting-edge collaborative R&D projects have achieved milestones at various stages. In partnership with BrightGene Bio-Medical, the Group co-developed BGM0504 injection, for which the new drug application for the weight-loss indication has been accepted by the National Medical Products Administration (the "**NMPA**"). Study data demonstrated that the drug has shown certain improvements in blood pressure, blood lipids, uric acid and glycometabolic indicators, and suggested that there is no risk of bone loss during the weight-loss process. Jointly with Nanjing Help Therapeutics, the Group developed HiCM-188, which has now initiated confirmatory clinical trials. This drug is the world's first innovative drug for heart failure regenerative therapy based on induced pluripotent stem cells that has simultaneously obtained clinical trial tacit approvals in both the PRC and the United States. In collaboration with the Hong Kong Nano and Advanced Materials Institute (NAMI) and Fudan University, the Group has developed a novel nano-formulation for the treatment of Alzheimer's disease, which has successfully completed its first-phase milestone review. Furthermore, the Group has established multiple joint laboratories with over 30 leading universities and research institutions, including Tsinghua University, Zhejiang University, University of Macau, China Academy of Chinese Medical Sciences, Shenyang Pharmaceutical University, Beijing University of Chinese Medicine, and Shanghai University of Traditional Chinese Medicine, among others, to continuously advance cooperation in areas such as synthetic biology, continuous manufacturing and intelligent TCM.

Accelerating the transformation and implementation of innovative achievements. The Group is accelerating the transformation and application of core achievements in fields such as classic TCM formulas, modern TCM, chemical drugs, biological drugs, and synthetic biology. As of the end of the Reporting Period, the Group had a total of 359 R&D projects under development, including 130 new drugs. During the Reporting Period, the Group obtained 26 drug production approvals and 4 clinical trial approvals.

In terms of innovative TCM achievements, during the Reporting Period, the Group's Class 1.1 innovative TCM drug, Zao Ren Ning Xin Dripping Pills, was approved for marketing, representing the first and only innovative TCM drug approved in the PRC in the first half of the year. Three classic TCM formulae, namely Taohe Chengqi Tang Granules, Dajianzhong Tang Paste and Jichuan Jian Granules, obtained the Pharmaceutical Product Registration Certificates. In addition, one Class 1 innovative TCM drug has been submitted for market approval, one Class 1 new drug has completed Phase III clinical studies and submitted for pre-NDA, and two classic TCM formulae have passed the on-site inspection for market registration applications; five Class 1 new drugs are currently in Phase III clinical studies. Compound E-Jiao Syrup has been included in the Clinical Practice Guidelines for the Diagnosis and Treatment of Cancer-Related Fatigue in China (2026 Edition), becoming the only newly added recommended TCM treatment in the updated guidelines. The Phase II clinical trial of Compound E-Jiao Syrup in the treatment of cancer-related fatigue is progressing steadily.

In terms of innovative R&D achievements in chemical drugs, during the Reporting Period, the Group's one Class 2.3 new drug, which is the world's first and only Class 1A drug for the treatment of rare disease — Charcot-Marie-Tooth disease, is currently under review with supplementary information requested; one Class 2.2 new drug for the treatment of type 2 diabetes mellitus had submitted a marketing application; ONC201 capsules had been included by the CDE in the "Starlight Program", with a proposed indication for children aged 6 to 18 years with relapsed or progressive H3K27M-mutant DMG; the Group's Class 1 innovative antidepressant drug had entered a Phase IIb clinical study; DC6001, a Class 1 new drug for the treatment of macular degeneration, achieved dual filing in China and the United States and obtained clinical trial approvals and had obtained FDA Pediatric Rare Disease Designation; and DC7001A, a Class 1 new drug for the treatment of systemic lupus erythematosus, had been filed simultaneously in China and the United States.

In terms of generic chemical drug R&D, the Group further enriched its product pipeline in fields such as dermatology, digestive diseases, metabolism and cardiovascular diseases. 18 generic chemical drugs, including Adapalene Gel, Linagliptin and Metformin Hydrochloride Tablets and Vortioxetine Hydrobromide Tablets, obtained marketing authorizations for production, while 3 products, including Propranolol Hydrochloride Injection and Desloratadine Tablets, passed the consistency evaluation.

In terms of innovative R&D achievements in biological drugs, during the Reporting Period, the Group's human coagulation factor IX obtained the Clinical Trial Approval Notice issued by the NMPA. In July 2026, the Group's human von Willebrand factor obtained the Clinical Trial Approval Notice from the NMPA. This was a new application submitted following process optimization for product quality control after the original approval had been obtained, demonstrating the Group's continuous pursuit of the safety and stability of its products for clinical use.

c. Building a second growth curve and creating new growth momentum

Building a closed-loop synthetic biology industry chain. Shenzhou Biology & Technology, a subsidiary of the Group, is committed to building full industry-chain capabilities spanning strain development to preparation. Leveraging its R&D capabilities, low-cost operating system and integrated coordination between active pharmaceutical ingredients and preparation, the Group has established competitive advantages underpinned by industry-leading fermentation yields and highly competitive costs. Through the application of synthetic biology technologies, the Group has optimised strains and improved production processes for its core products, coenzyme Q10 and S-sodium salt, resulting in continuous cost reductions and significant increases in production output. The global market share of coenzyme Q10 has risen to rank first in the industry. The potential product 1,4-butanediamine has achieved mass production through synthetic biology processes. Compared with traditional chemical production routes, it offers advantages including a green and low-carbon profile, controllable costs and significant differentiation in production processes, and its industry development direction is highly aligned with the national "Dual Carbon" strategy. Its downstream applications cover industries including engineering plastics, automobiles and electronics, providing substantial room for market development. In May 2026, Shenzhou Biology & Technology entered into a deep strategic cooperation agreement with Shenzhen Wote Advanced Materials Co., Ltd., pursuant to which the parties will work together to build a globally competitive bio-based materials industry chain and provide highly resilient and risk-resistant localized material solutions for downstream industries including new energy, advanced manufacturing and biopharmaceuticals. Shenzhou Biology & Technology has obtained the qualification for Production Licence for Compound Feed Additives, enabling the commercial application of coenzyme Q10 fermentation residues in the field of feed additives and effectively enriching its product portfolio. In terms of capacity expansion, the coenzyme Q10 purification and refining production line with an annual capacity of 1,000 tonnes passed the on-site audit and certification of the United States Pharmacopeia

("**USP**") and was successfully put into operation. This marks that Shenzhou Biology & Technology's quality control system has reached internationally leading standards and lays a solid foundation for further developing overseas markets. In addition, in July 2026, CR Double-Crane announced that it proposed to acquire, by way of cash consideration, 188 million shares of Lier Chemical Co., Ltd. ("**Lier Chemical**"), representing 23.50% of its total issued share capital. Upon completion of the transaction, CR Double-Crane will become the controlling shareholder of Lier Chemical. Lier Chemical is principally engaged in the R&D, production and sale of high-efficiency, low-toxicity and low-residue pesticide technical materials, including chloropyridine pesticides and organophosphorus pesticides. It is the largest manufacturer of chloropyridine pesticide technical materials and formulations in China, as well as a large-scale manufacturer of glufosinate-ammonium and L-glufosinate technical materials in China. It has also established a synthetic biology manufacturing industrial platform, with full-chain capabilities ranging from engineered strain construction, pilot-scale testing to commercial-scale production. CR Double-Crane has developed a number of products in the field of synthetic biological pesticides; however, it currently lacks an industrialisation platform for commercial implementation. Through this transaction, the industrialisation of synthetic biology technology products can be rapidly achieved. Lier Chemical may leverage CR Double-Crane's leading synthetic biology technologies and corporate management experience to enhance its product competitiveness and market position. The two parties have strong business synergies, which will facilitate CR Double-Crane in establishing a second growth curve in synthetic biology, thereby contributing to the development of a leading benchmark enterprise in the synthetic biology industry.

Continuously strengthening professional academic marketing capabilities. In terms of prescription medicines, the Group consistently enhanced its academic promotion and service capabilities in specialised therapeutic areas. CR Double-Crane accelerated the incubation of differentiated specialty products: Teniposide and Brivudine, strengthened brand visibility through high-frequency academic conferences and multi-platform promotional activities, with revenues growing 52% and 32% year-on-year, respectively. Yiqi Qingfei Granules of CR Sanjiu preliminarily completed a presence across eight major regions in China, and added over 200 new cooperative terminals in the first half of the year. CR Boya Bio-pharmaceutical continued to drive the transformation of its marketing model toward "medical academic + brand value". Meanwhile, the Group has comprehensively deepened the development of clinical evidence-based medicine for products introduced through cooperation and actively strengthened the expansion of its terminal network. CR Double-Crane facilitated the successful inclusion of Fespixon® in the Chinese

Expert Consensus on the Management of Lower Extremity Atherosclerotic Occlusive Disease in the Elderly, and took the lead in advancing the International Expert Consensus on the Role of Herbal Medicines in Diabetic Foot Ulcer Healing. It also continued to strengthen the evidence base, driving the translation of academic outcomes for the HICARA® into clinical practice, thereby reinforcing its benchmark position as a domestic CAR-T product, broadening multi-dimensional accessibility in terms of terminal, reimbursement, and services, and securing its inclusion in the "Shanghai Hu Hui Bao Health Insurance (上海滬惠保)" formulary. In parallel, CR Sanjiu, for its rare-disease product Wakix®, established a full-chain promotion system encompassing academic consensus, hospital access, and patient conversion.

Activating market momentum in the CHC segment. In the OTC and health consumer products arena, the Group continued to elevate brand equity, intensify new product launches and channel development, and further solidify its industry leadership and competitive edge. CR Sanjiu actively expanded its presence in market segments within the respiratory category, with a significant increase in sales revenue from Huoxiang Zhengqi. Dong-E-E-Jiao's consumer health business adopted a systematic "brand + product + scenario + promotion" strategy to drive omnichannel marketing deployment. Its health consumer products, "Little Gold Bar" E-Jiao Powder, and "Yuyuanqi" E-Jiao Jujubes, achieved rapid year-on-year revenue growth, while products such as the "Royal Hunting Ground" series and Sam's-customised E-jiao Astragalus Powder continued to gain traction in key channels. CR Jiangzhong's probiotic series leveraged strong brand recognition and the technological advantage of its proprietary "P9" strain, while extending into weight-management and other sub-categories to build a differentiated portfolio tailored to diverse customer needs. It also actively explored incremental opportunities in interest-based e-commerce, resulting in significant year-on-year revenue growth. In addition, CR Jiangzhong proactively expanded into the Foods for Special Medical Purposes (FSMP) segment. During the Reporting Period, it signed a strategic cooperation framework agreement with "DAESANG Wellife", the health-focused brand of South Korea's prominent integrated food group Daesang Corporation, to jointly develop the domestic FSMP and broader health industry. It also explored to establish cross-border e-commerce channels to facilitate the introduction of professional nutrition products that have been well-established in overseas markets.

d. Deepening smart manufacturing and empowering operational excellence through digitalisation

Smart manufacturing capabilities gained authoritative recognition. The Group's pharmaceutical manufacturing segment has been deeply engaged in smart manufacturing, continuously driving the transformation and upgrading of production bases. During the Reporting Period, its digital intelligence achievements received authoritative recognition. Specifically, five of the Group's manufacturing sites were accredited as national "Advanced-level" smart factories. CR Sanjiu actively participated in the formulation of national digital transformation standards and published an industry blue paper on smart manufacturing, leading the digital intelligence development of the TCM industry. CR Jiangzhong was recognized by the Ministry of Industry and Information Technology ("**MIIT**") as a "Four-Star Outstanding Enterprise in Digital Transformation Maturity", becoming the second pharmaceutical company in China to receive this qualification. CR Double-Crane Beijing Industrial Park was listed in the MIIT's 2025 typical case catalogue for digital transformation under the "Digital Trio" (variety, quality, brand) initiative. Dong-E-E-Jiao was honored with the title of "Four-Star Outstanding Unit for Digital Transformation Standards Application". CR Boya Bio-pharmaceutical was named a "2026 Jiangxi Provincial Advanced-level Smart Factory".

Advancing marketing transformation. During the Reporting Period, the Group comprehensively advanced the digital and compliant transformation and upgrade of its marketing, continuously improved the digital infrastructure in its marketing and sales processes, innovated brand communication approaches, and enhanced consumer experience and service standards. During the Reporting Period, the online business revenue of the pharmaceutical manufacturing segment recorded a year-on-year increase of over 21%. CR Double-Crane leveraged its digital platform to establish an online full-process management system for peritoneal dialysis patients, providing functions such as patient registration, follow-up, and health education. CR Jiangzhong established a digital compliance operation platform, strengthening compliance management. CR Sanjiu strengthened its online channel development and advanced its strategic cooperation with JD Health. Dong-E-E-Jiao comprehensively advanced the development of its omni-channel membership system, integrating data of 7.27 million members and establishing a customer operation system that connects public and private domains.

Advancing excellent operation. The Group accelerated the deep integration of digital and intelligent technologies with lean management, comprehensively enhancing the quality and efficiency of operational management across all aspects and the entire value chain. CR Sanjiu developed intelligent testing equipment with proprietary intellectual property rights, significantly improving testing efficiency. The Synthetic Biology Research Institute under CR Double-Crane leveraged artificial intelligence to conduct a series of research, encompassing key areas such as mining and rational design of biological components, mining and directed rational engineering of key industrial enzymes, as well as protein virtual evolution and intelligent high-throughput sequence screening. It also advanced the establishment of AI-driven fermentation process modeling and process optimization systems. CR Jiangzhong built a multi-source knowledge graph and leveraged AI technology to support intelligent R&D, and received the First Prize of the China Quality Lean Site Project during the Reporting Period. Dong-E-E-Jiao fully upgraded and deployed its EMS energy management system, contributing to an overall energy saving rate of 25%. CR Boya Bio-pharmaceutical preliminarily achieved millisecond-level intelligent monitoring of aseptic operations.

e. Actively promoting international expansion and continuously exploring international markets

The Group continued to accelerate its international business layout, established an international sales team, and comprehensively expanded its international markets, charting a new development landscape with a global vision. During the Reporting Period, the Group's pharmaceutical manufacturing segment recorded export revenues of approximately RMB700 million.

In terms of international product registration, the Group had obtained more than 500 overseas drug registration numbers in aggregate. During the Reporting Period, the enoxaparin sodium injection under CR Double-Crane saw orderly progress in multi-country registrations; mifepristone tablets newly obtained registration qualifications in El Salvador and Kyrgyzstan; sodium valproate API obtained the European (EDQM) CEP certificate. Dong-E-E-Jiao completed drug registration in Hong Kong for its E Jiao Buxue Granules, and its E Jiao products successfully passed the product quality test of the Hong Kong Standards and Testing Centre and were awarded the "STC Certified" Mark certification.

In terms of channel expansion, CR Double-Crane actively built an international team. During the Reporting Period, export revenue from its API and synthetic biology businesses increased by 11% and 43% year-on-year, respectively, while sales of enoxaparin sodium in the Russian market continued to grow. Dong-E-E-Jiao's products were launched on HKTVmall, Hong Kong's largest online shopping platform, and City'super, a premium supermarket chain, while its Huangqi Jing product successfully completed its first overseas shipment to Australia. KPC promoted the expansion of its Xuesaitong product series into European, American, and Southeast Asian markets, and continued to develop the African market for its Dihydroartemisinin-Piperaquine Tablet (Cotefiz®). During the first half of the year, it completed two foreign aid training programs, covering 14 countries with a focus on AIDS and malaria prevention and control.

Expanding overseas markets for medical devices. The Group has advanced the registration applications and sales of medical devices in over 50 countries, with export sales revenue increasing by 42% year-on-year during the Reporting Period. Its plasma collection product series holds a market share of over 20% in Europe, ranking first in the Netherlands, Denmark, and other countries. During the Reporting Period, the Group obtained a registration certificate for its blood component separator in Indonesia, three initial registration certificates for its plasma collection machines in Iran and Egypt.

3. Pharmaceutical Distribution and Retail Business

(1) Financial performance

During the Reporting Period, the Group's pharmaceutical distribution business recorded segment revenue of RMB110,994.8 million, representing a year-on-year increase of 2.5%. The gross profit margin of the distribution business was 5.7%, representing a slight decrease of 0.2 percentage points compared with the same period of last year.

During the Reporting Period, the Group's pharmaceutical retail business recorded revenue of RMB6,337.2 million, representing a year-on-year increase of 14.9%. The Direct To Patient (DTP) business achieved revenue of approximately RMB4.83 billion, representing a year-on-year growth of 28.6%. The gross profit margin of the retail business was 6.3%, representing an increase of 0.2 percentage points compared with the same period of last year.

(2) Business performance

As of the end of the Reporting Period, the Group's pharmaceutical distribution network has covered 28 provinces across China, serving nearly 100,000 clients. The Group operated a total of 1,228 self-owned retail pharmacies, including 265 "DTP pharmacies", professional direct-to-patient pharmacies (including 211 "dual-channel" pharmacies).

a. Driving the professional development of in-depth marketing navigated by high-standard compliance

Through multiple initiatives encompassing "professional organisation + high-standard compliance + digital operations", the Group has accelerated the development of its in-depth marketing business covering oncology, chronic diseases, rare diseases and retail channels, with products involving a number of multinational corporations (MNCs) and leading domestic pharmaceutical enterprises. During the Reporting Period, revenue from the in-depth marketing business exceeded RMB3.5 billion. The Group has continued to strengthen its high-standard compliance operating system aligned with international standards, establishing an integrated, end-to-end compliance mechanism covering the entire chain of its in-depth marketing business. It has successfully passed project compliance audits conducted by several leading MNCs, and its high-standard compliance framework has become a core competitive advantage in expanding upstream partnerships. The Group has persistently advanced the integrated system development of its in-depth marketing business, establishing a development model featuring synergy between headquarters and regional operations. It has also continuously reinforced its IT infrastructure, further enhancing management efficiency and operational effectiveness through system upgrades and iterations. During the Reporting Period, the Group advanced the largest in-depth marketing project in the oncology segment currently within the industry, and collaborated with Roche Pharmaceutical and Novo Nordisk in the oncology and chronic disease areas with two new products added, "Kadcyla" and "Novonorm". Furthermore, the Group innovated its cooperation model by signing domestic responsible party transaction agreements with upstream pharmaceutical enterprises, upgrading the national distribution rights for certain products to the rights of the domestic responsible party within Chinese Mainland. With its core brand "Runyao", the Group continued to refine its dual-driven academic promotion platform integrating "in-hospital precision academic + out-of-hospital terminal sales activation". At the same time, it steadily expanded its marketing channels and deepened collaborations with leading e-commerce platforms such as JD.com.

b. Accelerating the professional development of the medical device business and enhancing innovation service capabilities

During the Reporting Period, the Group's device distribution business expanded rapidly, with continuous efforts to strengthen integrated management and professional operations, achieving revenue of RMB20.5 billion, representing a year-on-year increase of 14%. The Group consistently reinforced its professional capabilities in specialized product lines, including orthopedics, interventional products, IVD, and general consumables, while actively building a professional national distribution network. In the interventional product line, new product lines from leading international companies were added, driving a 26% year-on-year revenue growth. The general consumables segment recorded a 12% year-on-year revenue increase, while the orthopedics segment accelerated its expansion into the sports medicine business. In parallel, the Group actively incubated new business areas, with the hemodialysis and neurosurgery segments achieving rapid revenue growth of 23% and 22%, respectively. During the Reporting Period, the Group continued to expand its presence upstream in the medical device industry chain, strengthening its own brand of basic consumables "Runyaoxin". It obtained 10 new self-owned product registration certificates during the Reporting Period, bringing the total number of self-owned product registration/filing certificates to 86. The innovative "free consumables package" business model was adopted in 12 new hospital clients. The Group further enhanced its innovation service capabilities in the device business, and has established a professional SPD company and developed its own SPD service software. During the Reporting Period, it added 45 new SPD and centralized distribution projects and rolled out unified service standards for its SPD business to systematically improve its terminal service capabilities.

c. Strengthening integrated upstream resource development and expanding comprehensive import service capabilities

The Group's distribution business continued to strengthen its integrated supply chain capabilities across the entire value chain by unifying standards for new product assessment, manufacturer engagement and commercial negotiations, while coordinating efforts to secure high-quality upstream resources. During the Reporting Period, the Group extensively engaged leading upstream manufacturers, introducing 6 newly contracted business development ("**BD**") products and 112 nationally negotiated drugs, while securing commercialisation rights for 20 newly approved innovative medicines, thereby efficiently enriching its portfolio of high-quality products. In March 2026, China Resources Pharmaceutical Commercial Group Company Limited ("**CR Pharmaceutical Commercial**")

officially entered into a cooperation agreement with Roche. Leveraging their respective strengths in pharmaceutical distribution, integrated marketing and innovative R&D, the two parties will jointly promote the commercialisation of T-DM1, a therapy for breast cancer, in Chinese Mainland. In July 2026, CR Pharmaceutical Commercial entered into a strategic cooperation agreement with Innovent Biologics. The two parties will focus on market access, supply chain security and stability, patient care and extensive market coverage, with a view to establishing an integrated "industry + commerce + healthcare" ecosystem and creating a benchmark model for collaboration between pharmaceutical manufacturers and distributors.

During the Reporting Period, the Group further strengthened the acquisition of imported products through its "multi-port, one-stop" service model, introducing 4 key imported products and generating sales of imported products amounting to RMB6.2 billion. The Group also actively explored opportunities to introduce overseas products in therapeutic areas including respiratory diseases, central nervous system disorders and rare diseases. Meanwhile, leveraging green channels across multiple ports of entry, the Group accelerated the introduction of clinically urgently needed innovative pharmaceuticals and medical devices into China by capitalising on the policy opportunities offered by the Hong Kong and Macao Drug and Medical Device Transit and the Boao Lecheng Special Zone's pilot program for licensed medical devices, thereby facilitating introduction of clinically urgent products.

d. Advancing digital marketing platform development and enhancing operational efficiency through intelligent technologies

The Group continued to deepen the breadth and depth of its digital marketing capabilities by further enhancing its e-commerce platform ecosystem. Through the integration of end-to-end data across platforms including "CR Pharma e-Store (潤藥商城)", "Runyao Available (潤曜通)" and "Run Care (潤關愛)", the Group strengthened its capabilities in proactive customer insights and precision services, while launching digital marketing solutions for pharmaceutical manufacturers. During the Reporting Period, the Group's online platforms recorded gross merchandise value of approximately RMB18.1 billion, representing a year-on-year increase of 14%.

The Group also continued to strengthen the development of its intelligent logistics system. During the Reporting Period, construction of two benchmark smart logistics hub projects progressed steadily. The CR Pharmaceutical Commercial Supply Chain (Guangdong) Project, with a planned gross floor area of 106,000 square meters, has been included in the list of key projects of Guangdong Province and the national core cold-chain logistics base programme. Upon completion, it will serve as the Group's core logistics hub in South China, effectively reducing regional integrated logistics costs while enhancing the cross-border supply chain support capability under the "Hong Kong and Macao Drug and Medical Device Transit". The CR Pharmaceutical Commercial Smart Supply Chain (Beijing) Project, with a planned gross floor area of 113,000 square meters, has been designated as a key project of Beijing Municipality. Leveraging the integrated air-rail transportation advantages of Beijing Daxing International Airport, the project will establish two-way import and export channels for pharmaceuticals and medical devices, supporting the development of pharmaceutical emergency reserve capabilities in the Beijing-Tianjin-Hebei region and international pharmaceutical trading business. The Group's "Runyao IoT (潤曜物聯)" platform has achieved integrated multi-warehouse collaborative management across all regions nationwide, enhancing supply chain efficiency and cost competitiveness. During the Reporting Period, the Group also launched the next-generation WMS 4.0 and TMS 2.0 projects to further drive the intelligent upgrading of its logistics network.

Regarding operation, the Group continued to leverage digital intelligence to enhance end-to-end operational management efficiency, further standardising and streamlining operating processes. At the same time, the Group implemented a series of "AI+" initiatives, developing intelligent agent applications across dozens of key business scenarios, including finance and procurement, to promote the intelligent transformation of operations and management decision-making.

e. Strengthening the development of professional pharmacies to boost pharmaceutical management and pharmaceutical service capabilities

In terms of retail business, the Group has continuously strengthened operational planning and standardized management controls to build professional, standardized, and high-quality pharmacies. During the Reporting Period, the Group implemented a retail business strategy of "professional pharmaceutical service + AI-driven digital intelligence", and actively promoted the development of the pharmacist team, full-course patient management, the uptake of innovative drug prescription outflow, and the application of AI technologies to further enhance operational quality. In terms of professional capability building, the Group introduced senior chief pharmacists to establish a full-course pharmaceutical service system; through training and certification programs, it strengthened specialized intervention capabilities for specific disease types. The number of pharmacists deeply involved in patient management has increased by over 30% year-on-year, and the number of effective service-covered patients has grown by more than 50% year-on-year. Furthermore, by integrating "in-hospital + out-of-hospital" pharmaceutical service scenarios, the Group has expanded the service boundaries of professional pharmacies. The Group has proactively laid out out-of-hospital channels for innovative drugs, focusing on newly approved Class 1.1 innovative drugs and Class 1.4 modified new drugs. During the Reporting Period, the availability rate of such drugs in retail stores increased by over 50% year-on-year, effectively expanding the core prescription drug product portfolio. The Group continued to upgrade its proprietary patient management platform, leveraging digital and intelligent measures to enhance precise patient profiling and segmented operations, and systematically strengthened patient adherence management. During the Reporting Period, the repurchase conversion rate of existing patients increased by over 50% year-on-year.

4. ESG and Sustainable Development

The Group has deeply integrated the ESG philosophy into the entire process of corporate operation and strategy, continuously built its ESG brand, and deepened its sustainable development system with "governance as the foundation, society as the value driver and environment as the responsibility". The Group further strengthened its management capabilities across environmental, social, and governance domains to achieve green and high-quality development.

a. Continuously improving the ESG system to enhance overall governance effectiveness

The Group has continuously deepened and advanced its ESG management system tailored to the characteristics of the pharmaceutical industry, remaining committed to maintaining high standards of corporate governance and systematically advancing the implementation of sustainable development. During the Reporting Period, the Group maintained an MSCI ESG rating of A and a Wind ESG rating of AA, and continued to be included in the Hang Seng SCHK China Central State-owned Enterprises ESG Index. Tasly Pharmaceutical maintained a Wind ESG rating of AAA; CR Sanjiu maintained a Wind ESG rating of AA; and CR Double-Crane, CR Jiangzhong, Dong-E-E-Jiao, and CR Boya Bio-pharmaceutical all maintained a Wind ESG rating of A. These ratings demonstrated the capital market's recognition of the Group's ESG management capabilities and long-term investment value. The Group continuously improved its corporate governance standards, deepened state-owned enterprise reforms, and comprehensively stimulated its endogenous innovation vitality. CR Sanjiu has been honored with the highest rating of "Benchmark" in the State-owned Assets Supervision and Administration Commission's Sci-Tech Reform Action for the fourth consecutive year, reflecting the full recognition of its reform achievements.

b. Advancing the energy transition and fulfilling the corporate responsibility as a green citizen

The Group has consistently adhered to the philosophy of green and low-carbon development. During the Reporting Period, it steadily rolled out rooftop distributed photovoltaic projects with a total installed capacity of 12.3 MW, which are expected to provide over 13 million kWh of clean electricity annually and reduce carbon emissions by approximately 7,500 tons per year. Aino (China) Pharmaceutical Co., Ltd. (澳諾(中國)製藥有限公司), a subsidiary of the Group, was awarded the title of "National Green Factory", and CR Boya Bio-pharmaceutical was recognized as an "Outstanding Case of Beautiful Factory Construction" in Jiangxi Province. In terms of zero-carbon demonstration and carbon footprint, China Resources Sanjiu (Chenzhou) Pharmaceutical Company Limited (華潤三九(郴州)製藥有限公司) was included in Hunan Province's zero-carbon factory pilot list, and Wuhan Binhu Double-Crane Pharmaceutical Park was among the first batch of industrial parks in Hubei

Province to be certified as a zero-carbon park. Several products of the Group, including Compound E-jiao Jiang, apheresis plasma separators, and Ganmao Ling Granules, have completed carbon footprint certification. Meanwhile, the Group has actively participated in the formulation of green and low-carbon group standards to facilitate the green and sustainable development of the industry. The case of CR Jiangzhong, titled "Turning 'Waste' into 'Treasure' in Traditional Chinese Medicine and Moving Factories Toward 'Zero' Carbon", was selected as a practical case in the "Zero-Waste City" construction initiative of the three provinces in the middle reaches of the Yangtze River. In addition, CR Jiangzhong took the lead in drafting the Guidelines for Low-Carbon Operation and Management of Traditional Chinese Medicine Factories (《中醫藥工廠低碳運營管理指南》), and participated in the formulation of the Evaluation Standards for Zero-Carbon Factories — Pharmaceutical Industrial Enterprises (《零碳工廠評價規範 — 醫藥工業企業》).

OUTLOOK AND FUTURE STRATEGY

China Resources Pharmaceutical remains committed to its mission of "Protecting Human Health and Improving Quality of Life", with the vision of becoming a trusted, innovation-driven leader in the pharmaceutical and healthcare industry.

Looking ahead to the "15th Five-Year Plan", the Group will closely align with national strategic priorities and public health needs, focus on strategic emerging industries, continuously optimize its industrial layout and business structure, and consolidate the strategic foundation for high-quality corporate development. Taking scientific and technological innovation as the cornerstone, the Group will keep improving its innovation system, pooling innovation resources, and systematically enhancing its capabilities in key technology breakthroughs, achievement commercialization, and iterative upgrading, so as to accumulate the fundamental driving force for sustained corporate growth. Adhering to the dual-wheel-driven synergy of connotation quality improvement and external expansion, the Group will consolidate its industry position, strengthen core competitive advantages, and drive the steady enhancement of its overall strength. It will systematically build up capabilities in scientific and technological innovation, industrial control, and security support to ensure the enterprise's steady and far-reaching development, and safeguard public health with a solid industrial foundation.

1. **Serving national strategies and optimizing industrial layout.** The Group will continuously ramp up efforts in the layout of strategic emerging industries, vigorously develop sectors including biological drugs, blood products, high-end medical devices, and synthetic biology, and carry out full-value-chain management of the TCM industry in an all-round manner. It will focus on strengthening academic leadership to expand high-quality serious medicine, broaden business boundaries to grow the consumer healthcare sector, deepen cultivation in niche tracks to build specialized medical device capabilities, and optimize business structure to enhance pharmaceutical distribution services, so as to achieve remarkable improvement in business structure and quality and accelerate the growth of strategic emerging businesses.

2. **Tackling key scientific and technological innovation challenges to build growth momentum.** Guided by patient and clinical demands, the Group will improve innovative technology platforms, prioritize differentiated layout of new product pipelines, accelerate the construction of national key laboratories and national engineering technology research centers, and continuously refine the diversified innovation strategy covering independent R&D, external cooperation, and product introduction, to effectively boost the enabling role of technology.

3. **Adhering to external expansion and integrating industrial resources.** Seizing industrial opportunities, the Group will improve its industrial layout through investment, mergers and acquisitions, and resource integration. It will comprehensively adopt diversified investment tools such as direct industrial investment and industrial funds, and adopt a proactive, prudent and flexible investment strategy to address business weakness and optimize business structure. The Group will focus on strengthening post-investment management, promote two-way integration and synergy to generate greater efficiency, and achieve high-quality business development.

4. **Pursuing operational excellence to consolidate the foundation for development.** Benchmarked against the world-class enterprise standards of "product excellence, brand eminence, innovation leadership and modern governance", the Group will carry out in-depth differentiated categorized management, thoroughly implement lean management, strengthen the development of the compliance system and operational risk prevention, promote the coordinated progress of management efficiency improvement and operational quality enhancement, and continuously consolidate the foundation for high-quality development.

5. **Strengthening smart digital empowerment to boost business upgrading.** The Group will fully leverage advanced technologies to reshape business processes, deepen the implementation of smart manufacturing, actively explore the application of new technologies such as artificial intelligence in R&D, supply chain, sales and other links, and comprehensively improve the operational efficiency and quality of the enterprise.

LIQUIDITY AND FINANCIAL RESOURCES

The Group adopts a prudent treasury management policy to maintain a solid and healthy financial position.

The Group funds its operations principally from cash generated from its operations, bank loans and other debt instruments and equity financing from investors. Its cash requirements relate primarily to production and operating activities, business expansion, repayment of liabilities as they become due, capital expenditures, interest and dividend payments.

As at 30 June 2026, the Group had cash and cash equivalents of RMB15,622.4 million (31 December 2025: RMB15,843.8 million), which were denominated primarily in RMB and HK$.

As at 30 June 2026, all of the Group's total borrowings are RMB-denominated. Among the total borrowings as at 30 June 2026, a substantial portion of approximately 89.1% (31 December 2025: 81.0%) would be due within one year.

As at 30 June 2026, the Group's current ratio (being the ratio of total current assets to total current liabilities) was 1.4:1 (31 December 2025: 1.4:1).

As at 30 June 2026, the Group's gearing ratio (being the ratio of net debt divided by total equity) was 52.0% (31 December 2025: 47.4%).

In the first half of 2026, the Group's net cash generated from operating activities amounted to RMB1,423.1 million (in the first half of 2025: net cash generated from operating activities of RMB1,531.0 million). In the first half of 2026, the Group's net cash used in investing activities amounted to RMB636.0 million (in the first half of 2025: net cash used in investing activities of RMB5,017.3 million). In the first half of 2026, the Group's net cash used in financing activities amounted to RMB1,004.9 million (in the first half of 2025: net cash generated from financing activities of RMB4,731.2 million).

As at 30 June 2026, the Group had not used any financial instruments for hedging purposes (31 December 2025: nil).

PLEDGE OF ASSETS

As at 30 June 2026, the Group's total borrowings amounted to RMB59,392.0 million (31 December 2025: RMB58,820.2 million), of which RMB2,179.2 million (31 December 2025: RMB2,462.7 million) were secured and accounted for 3.7% (31 December 2025: 4.2%) of the total borrowings.

As at 30 June 2026, certain of the Group's trade and bills receivables with an aggregate net book value of RMB1,485.8 million (31 December 2025: RMB1,602.6 million) have been pledged as security.

CONTINGENT LIABILITIES

As at 30 June 2026, the Group had no material contingent liabilities (31 December 2025: nil).

SIGNIFICANT INVESTMENTS HELD AND MATERIAL ACQUISITIONS AND DISPOSALS

During the Reporting Period, the Group did not have any significant investments and/or material acquisition or disposal of subsidiaries, associates and joint venture.

FUTURE PLANS FOR MATERIAL INVESTMENT OR CAPITAL ASSETS

As at the date of this announcement, there are currently no concrete plans to acquire any material investment or capital assets other than those conducted in the Group's ordinary course of business.

HUMAN RESOURCES

As at 30 June 2026, the Group employed around 84,000 staff in the PRC and Hong Kong. The Group remunerates its employees based on their performance, experience and prevailing market rate while performance bonuses are granted on a discretionary basis. Other employee benefits include, for example, medical insurance, training.

EVENTS AFTER THE REPORTING PERIOD

The Group had no significant subsequent events since the end of the Reporting Period and up to the date of this announcement.

INTERIM DIVIDEND

The Board has resolved to declare an interim dividend of RMB0.087 per share in cash for the six months ended 30 June 2026 (six months ended 30 June 2025: RMB0.072). The interim dividend will be distributed on 30 October 2026 (Friday) to the shareholders of the Company (the "**Shareholders**") whose names appear on the register of members of the Company on 15 September 2026 (Tuesday), being the record date for determining Shareholders' entitlement to the interim dividend. The interim dividend will be payable in cash to each Shareholder in HK$ by default, converted at the exchange rate of RMB1.0: HK$1.1561, being the average benchmark exchange rate of RMB to HK$ as published by the People's Bank of China during the five business days immediately before 24 August 2026 (Monday), such dividend will be paid to Shareholders at

HK$0.1006 per share. Shareholders will also be given the option to elect to receive all or part of the interim dividend in RMB. To make such election, Shareholders should complete the dividend currency election form which is expected to be despatched to Shareholders on or around 25 September 2026 (Friday), and lodge it with the Company's share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on 13 October 2026 (Tuesday).

Shareholders who are minded to elect to receive all or part of their dividends in RMB by cheques should note that (i) they should ensure that they have an appropriate bank account to which the RMB cheques for dividend can be presented for payment; and (ii) there is no assurance that RMB cheques can be cleared without material handling charges or delay in Hong Kong or that RMB cheques will be honoured for payment upon presentation outside Hong Kong. The cheques are expected to be posted to the relevant Shareholders by ordinary post on 30 October 2026 (Friday) at the Shareholders' own risk. If no duly completed dividend currency election form in respect of the Shareholder is received by the Company's share registrar by 4:30 p.m. on 13 October 2026 (Tuesday), such Shareholder will automatically receive the interim dividend in HK$. All dividend payments in HK$ will be made in the usual way on 30 October 2026 (Friday). If Shareholders wish to receive the interim dividend in HK$ in the usual way, no additional action is required. Shareholders should seek professional advice with their own tax advisers regarding the possible tax implications of the dividend payment.

CLOSURE OF THE REGISTER OF MEMBERS

The register of members of the Company will be closed from 14 September 2026 (Monday) to 15 September 2026 (Tuesday), in order to determine the entitlement of the Shareholders to receive the interim dividend, during which no share transfers will be registered. To qualify for the interim dividend, all properly completed transfer forms accompanied by the relevant share certificates must be lodged for registration with the Company's share registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not later than 4:30 p.m. on 11 September 2026 (Friday).

CORPORATE GOVERNANCE

The Group is committed to maintain high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability. The Company has adopted the Corporate Governance Code (the "**CG Code**") as set out in Appendix C1 to the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") as its own code of corporate governance. The Company has complied with all applicable code provisions of the CG Code during the Reporting Period, save and except the following:

In respect of code provision C.3.3 of the CG Code, the Company did not have formal letters of appointment for Directors. Since all Directors are subject to re-election by the Shareholders at the annual general meeting and at least once every three years on a rotation basis in accordance with the articles of association of the Company, there are sufficient measures to ensure the corporate governance of the Company complies with the same level to that required under the CG Code.

Code provision F.1.3 of the CG Code stipulates that the chairman of the Board should attend annual general meeting. The chairman of the Board was unable to attend the annual general meeting of the Company held on 12 June 2026 due to other business commitments.

The Company will continue to review and monitor its corporate governance practices to ensure compliance with the CG Code.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "**Model Code**") as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding directors' securities transactions. Having made specific enquiry of all the Directors, each of the Directors has confirmed that he/she has complied with the required standards as set out in the Model Code during the Reporting Period.

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the Reporting Period and up to the date of this announcement, neither the Company nor its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale or transfer of treasury shares). As at the end of the Reporting Period, the Company did not hold treasury shares (as defined under the Listing Rules).

REVIEW OF INTERIM RESULTS BY KPMG

The interim financial report for the six months ended 30 June 2026 is unaudited, but has been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements 2410 "Review of interim financial information performed by the independent auditor of the entity", issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report is included in the interim report to be sent to shareholders.

AUDIT COMMITTEE

The audit committee of the Company has reviewed the unaudited consolidated interim results of the Group for the six months ended 30 June 2026.

PUBLICATION OF THE INTERIM RESULTS AND 2026 INTERIM REPORT ON THE WEBSITES OF THE STOCK EXCHANGE AND THE COMPANY

This interim results announcement is published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.crpharm.com), and the 2026 interim report containing all the information required by the Listing Rules will be published on the aforesaid websites of the Stock Exchange and the Company and will be dispatched to Shareholders who have indicated that they wish to receive a printed version of the corporate communication.

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

Hong Kong, 24 August 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mdm. Zhang Jing and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.